Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/08/24
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 07/09/24
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101Seeking Alpha • 06/20/24
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual MeetingGlobeNewsWire • 06/03/24
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/24
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/09/24
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/23/24
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsGlobeNewsWire • 04/11/24
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/08/24
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceGlobeNewsWire • 03/19/24
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/14/24
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%Zacks Investment Research • 03/07/24
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/05/24
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/01/24
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ EditsGlobeNewsWire • 12/09/23
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus ErythematosusGlobeNewsWire • 12/06/23
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusGlobeNewsWire • 12/06/23
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewsWire • 11/21/23
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/23
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory DiseasesGlobeNewsWire • 11/09/23
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/26/23